Seoul, South Korea

Seon Mi Jo

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 17.0

ph-index = 1


Company Filing History:


Years Active: 2020-2021

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Seon Mi Jo: Innovator in Pharmaceutical Composition

Introduction

Seon Mi Jo is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address neurodegenerative diseases. With a total of two patents to her name, her work is paving the way for advancements in therapeutic agents.

Latest Patents

Her latest patents include an alpha-aminoamide derivative compound and a pharmaceutical composition comprising the same. This innovative compound is designed to overcome the limitations of existing drugs used as MAO-B inhibitors. The therapeutic agent reversibly inhibits MAO-B through a non-covalent bond, which helps alleviate or eliminate the side effects associated with traditional drugs that act irreversibly. The new compound demonstrates superior stability and efficacy compared to existing reversible MAO-B inhibitors, making it a promising candidate for treating neurodegenerative diseases.

Career Highlights

Throughout her career, Seon Mi Jo has worked with notable companies such as Neurobiogen Co., Ltd. and Megabiowood Co., Ltd. Her experience in these organizations has contributed to her expertise in pharmaceutical research and development.

Collaborations

Seon Mi Jo has collaborated with esteemed colleagues, including Ki Duk Park and ChangJoon Justin Lee. These partnerships have further enhanced her research and innovation in the pharmaceutical field.

Conclusion

Seon Mi Jo is a trailblazer in the development of pharmaceutical compositions, particularly in the area of neurodegenerative disease treatment. Her innovative work and collaborations are set to make a lasting impact on the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…